Tests THC effects on blood sugar in adults with type 2 diabetes
Tests THC on blood sugar in adults with type 2 diabetes.
Key facts
- Who runs it
- University of California, San Diego
- Where
- La Jolla, United StatesSee the site
- Trial code
- Registry title
- THC Effects on Glucose in Type 2 Diabetes
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 30 people, planned
- Started
- 22 Aug 2024
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- THC
- Placebo
- Record updated
- 15 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 21 to 70 with type 2 diabetes who take a stable medicine plan and do not use insulin. It tests the effect of THC on blood sugar and blood vessel function.
- Age
- 21 to 70 years
- Sex
- Men and women can join.
- Disease stage
- Type 2 diabetes diagnosed by a doctor, on stable medication for at least 3 months, with BMI over 25 kg/m2 and HbA1c under 10% (86 mmol/mol).
- Earlier treatment
- Must have taken a stable diabetes medication plan for at least 3 months. Must not have used any THC products in the 30 days before screening. Must not currently use insulin.
- Biomarker or test result
- Negative urine drug test at the screening visit.
Main reasons for not taking part
- Pregnant or breastfeeding
- Current use of insulin or tobacco products
- Past heart attack, stroke or heart failure
- Serious illness such as psychotic disorder, significant mood or anxiety disorder, liver or kidney disease
- History of seizures or serious problems after using cannabis
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Males and Females 21-70 years old at the time of screening
- Females of non-child bearing potential must be ≥ 1 year post-menopausal or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception during the entire study
- Male subjects must be willing to use clinically acceptable method of contraception during the entire study
- Have a clinical diagnosis of Type 2 Diabetes on a stable medication regimen for at least 3 months
- BMI > 25 kg/m2)
- HbA1c < 10%)
- Negative urine toxicology result at screening visit
- Able to provide written informed consent approved by an Institutional Review Board (IRB)
Who cannot take part
- No prior history of myocardial infarction, stroke or heart failure
- Use of any THC containing products within 30 days prior to the screening visit
- Liver enzymes ≥ 2 times upper normal limit and/or clinical signs/symptoms consistent with liver disease, including but not limited to nausea, vomiting, jaundice, itching, abdominal pain, or edema
- History of clinically significant adverse events associated with cannabis intoxication (e.g., severe anxiety and panic, paranoia and psychosis, sustained tachycardia, or severe hypotension)
- History of seizures, head trauma, or other history of CNS insult that could predispose the participant to seizures
- Current use of insulin to treat Type 2 Diabetes
- Any other condition(s) that might reduce the chance of obtaining study data, or that might cause safety concerns, or that might compromise the ability to give truly informed consent
- History or presence of any clinically significant illness, as detected by history, physical examination, and/or laboratory tests, that might put the participant at increased risk of adverse events (e.g., history of psychotic disorder, clinically significant mood and/or anxiety disorder, liver, or renal disease)
- Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations of plasma, packed RBCs, platelets or quantities less than 500 mL are allowed at investigator discretion
- Hemoglobin < 9g/dL
- Current use of tobacco products
- Individuals who are pregnant or lactating/breastfeeding
- Unable or unwilling to follow the study protocol or who are non-compliant with screening appointments or study visits
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
Where in United States
- UC San Diego Altman Clinical & Translational Research InstituteLa Jolla, United StatesContact: Todd May, MSTaking people
About the trial
What the trial wants to find out
This study will examine the effects THC has on Glucose Metabolism and Endothelial Functioning in participants with Type 2 Diabetes. The participants will complete blood tests and tests to measure energy expenditure, CVD risks, and glucose metabolism. These tests will be performed prior to start of treatment and again after 2-weeks of treatment with the THC or placebo.
The 2 groups in the trial
- Active THCExisting treatment, for comparison
Daily, inhaled, flexible dose of cannabis product with THC.
Treatment: THC and Placebo
- Placebo CannabisPlacebo, for comparison
Daily, inhaled, flexible dose of cannabis product without THC.
Treatment: THC and Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effects of THC on Glucose Metabolism and Endothelial Function in Subjects With Type 2 Diabetes
- Plain-language title
- Tests THC effects on blood sugar in adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05322213, who can take part
- Record updated
- 15 June 2026